*BIORESTORATIVE ANNOUNCES POSITIVE OUTCOME FROM TYPE B MEETING WITH FDA
*BIORESTORATIVE THERAPIES INC: CURRENTLY ANTICIPATES THAT PHASE 3 TRIAL IND SUBMISSION WILL BE MADE IN SECOND HALF OF 2026
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 11-FEB-202612:30:00.247 GMT